Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegoprazan DDI with Bismuth, Amoxicillin, and Clarithromycin in Healthy Subjects
NCT05915871Phase 1Completed
- Sponsor
- Shandong Luoxin Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegoprazan in Helicobacter pylori infection, sponsored by Shandong Luoxin Pharmaceutical. Primary endpoints: Area Under the Concentration-Time Curve Over the Dosing Interval at Day 27 and Maximum Plasma Concentration at Steady State at Day 27. Started Mar 2023; status: completed.
02
Drugs
tegoprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT05915871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05915871.